Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Open-Label, Dose Finding Study of NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibody, As a Single Agent, in Combination with Anti-PD-1 Antibody, and in Combination with Weekly Paclitaxel (Standard of Care) in Patients with Mesothelin Expressing Ovarian, Pancreatic, Non-Small-Cell-Lung and Triple-Negative Breast Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05403554
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:10.530250+00:00
Published At
2024-10-29T00:00:00+00:00
Record Updated At
2024-10-29
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Epithelial Ovarian Cancer", "Triple Negative Breast Cancer", "Non-squamous Non-small-cell Lung Cancer", "Pancreatic Adenocarcinoma (ductal Adenocarcinoma)", "Endometrioid Ovarian Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-10-29"
protocolSection.identificationModule.nctId
"NCT05403554"
protocolSection.identificationModule.officialTitle
"A Phase 1, Open-Label, Dose Finding Study of NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibody, As a Single Agent, in Combination with Anti-PD-1 Antibody, and in Combination with Weekly Paclitaxel (Standard of Care) in Patients with Mesothelin Expressing Ovarian, Pancreatic, Non-Small-Cell-Lung and Triple-Negative Breast Cancers"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Epithelial Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Non-squamous Non-small-cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Adenocarcinoma (ductal Adenocarcinoma) (protocolSection.conditionsModule.conditions)
  • Endometrioid Ovarian Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.